Something old, something new and something borrowed: Emerging paradigm of insulin-like growth factor type 1 receptor (IGF-1R) signaling regulation

Cellular and Molecular Life Sciences

Volumn 71, Issue 13, 2014, Pages 2403-2427

  Girnita, Leonard ^a   Worrall, Claire ^a   Takahashi, Shin Ichiro ^b   Seregard, Stefan ^c   Girnita, Ada ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF TOKYO   (Japan)

^c ST ERIK S EYE HOSPITAL   (Sweden)

Author keywords

Beta arrestins; Cancer; GPCR; GRKs; IGF 1R; IRS; RTK; Serine phosphorylation; Ubiquitination

Indexed keywords

G PROTEIN COUPLED RECEPTOR; MEMBRANE RECEPTOR; PROTEIN TYROSINE KINASE; SOMATOMEDIN C RECEPTOR;

CANCER THERAPY; DNA FLANKING REGION; HUMAN; HYBRID; NONHUMAN; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN TARGETING; RECEPTOR DOWN REGULATION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; TRANSACTIVATION; UBIQUITINATION;

ARRESTINS; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; RECEPTOR, IGF TYPE 1; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION; UBIQUITIN;

EID: 84903308286     PISSN: 1420682X     EISSN: 14209071     Source Type: Journal    
DOI: 10.1007/s00018-013-1514-y     Document Type: Review

References (298)

1. Lemmon MA, Schlessinger J (2010) Cell signaling by receptor tyrosine kinases. Cell 141(7):1117-1134
2. Aaronson SA (1991) Growth factors and cancer. Science 254(5035):1146-1153
3. Hupfeld CJ, Olefsky JM (2007) Regulation of receptor tyrosine kinase signaling by GRKs and beta-arrestins. Annu Rev Physiol 69:561-577 (Pubitemid 46457655)
4. Ullrich A, Schlessinger J (1990) Signal transduction by receptors with tyrosine kinase activity. Cell 61(2):203-212
5. Weiss A, Schlessinger J (1998) Switching signals on or off by receptor dimerization. Cell 94(3):277-280 (Pubitemid 28376070)
6. Heldin CH (1995) Dimerization of cell surface receptors in signal transduction. Cell 80(2):213-223
7. Heldin CH, Ostman A (1996) Ligand-induced dimerization of growth factor receptors: variations on the theme. Cytokine Growth Factor Rev 7(1):3-10 (Pubitemid 27202661)
8. Lemmon MA, Schlessinger J (1994) Regulation of signal transduction and signal diversity by receptor oligomerization. Trends Biochem Sci 19(11):459-463 (Pubitemid 24342757)
9. Carraway KL 3rd, Cantley LC (1994) A neu acquaintance for erbB3 and erbB4: a role for receptor heterodimerization in growth signaling. Cell 78(1):5-8
10. Schlessinger J (1997) Direct binding and activation of receptor tyrosine kinases by collagen. Cell 91(7):869-872
11. Ullrich A et al (1984) Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature 309(5967):418-425 (Pubitemid 14102443)
12. Roberts PJ, Der CJ (2007) Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 26(22):3291-3310 (Pubitemid 46763022)
13. Sell C et al (1994) Effect of a null mutation of the insulin-like growth factor I receptor gene on growth and transformation of mouse embryo fibroblasts. Mol Cell Biol 14(6):3604-3612 (Pubitemid 24160768)
14. Girnita A et al (2006) The insulin-like growth factor-I receptor inhibitor picropodophyllin causes tumor regression and attenuates mechanisms involved in invasion of uveal melanoma cells. Clin Cancer Res 12(4):1383-1391 (Pubitemid 43342532)
15. Baserga R, Peruzzi F, Reiss K (2003) The IGF-1 receptor in cancer biology. Int J Cancer 107(6):873-877 (Pubitemid 37429826)
16. Economou MA et al (2008) Inhibition of VEGF secretion and experimental choroidal neovascularization by picropodophyllin (PPP), an inhibitor of the insulin-like growth factor-1 receptor. Invest Ophthalmol Vis Sci 49(6):2620-2626
17. All-Ericsson C et al (2002) Insulin-like growth factor-1 receptor in uveal melanoma: a predictor for metastatic disease and a potential therapeutic target. Invest Ophthalmol Vis Sci 43(1):1-8 (Pubitemid 34032432)
18. Girnita L et al (2000) Inhibition of N-linked glycosylation down-regulates insulin-like growth factor-1 receptor at the cell surface and kills Ewing's sarcoma cells: therapeutic implications. Anticancer Drug Des 15(1):67-72 (Pubitemid 30364900)
19. Wang M et al (1999) Regulatory role of mevalonate and N-linked glycosylation in proliferation and expression of the EWS/FLI-1 fusion protein in Ewing's sarcoma cells. Exp Cell Res 246(1):38-46 (Pubitemid 29393744)
20. Girnita A et al (2004) Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth. Cancer Res 64(1):236-242 (Pubitemid 38114104)
21. Ulfarsson E et al (2005) Expression and growth dependency of the insulin-like growth factor I receptor in craniopharyngioma cells: a novel therapeutic approach. Clin Cancer Res 11(13):4674-4680 (Pubitemid 41557184)
22. Vasilcanu D et al (2006) The insulin-like growth factor-1 receptor inhibitor PPP produces only very limited resistance in tumor cells exposed to long-term selection. Oncogene 25(22):3186-3195 (Pubitemid 43881559)
23. Baserga R (2005) The insulin-like growth factor-I receptor as a target for cancer therapy. Expert Opin Ther Targets 9(4):753-768
24. Yin S et al (2010) Targeting the insulin-like growth factor-1 receptor by picropodophyllin as a treatment option for glioblastoma. Neuro Oncol 12(1):19-27
25. Furukawa J et al (2010) Antisense oligonucleotide targeting of insulin-like growth factor-1 receptor (IGF-1R) in prostate cancer. Prostate. 70(2):206-218
26. Gualberto A, Pollak M (2009) Clinical development of inhibitors of the insulin-like growth factor receptor in oncology. Curr Drug Targets 10(10):923-936
27. Gualberto A, Pollak M (2009) Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions. Oncogene 28(34):3009-3021
28. Tornkvist M et al (2008) Differential roles of SS18-SSX fusion gene and insulin-like growth factor-1 receptor in synovial sarcoma cell growth. Biochem Biophys Res Commun 368(3):793-800
29. Girnita L et al (2000) Increased expression of insulin-like growth factor I receptor in malignant cells expressing aberrant p53: functional impact. Cancer Res 60(18):5278-5283
30. Beauchamp MC et al (2010) Targeting insulin and insulin-like growth factor pathways in epithelial ovarian cancer. J Oncol 2010:257058
31. Jones JI, Clemmons DR (1995) Insulin-like growth factors and their binding-proteins: biological actions. Endocr Rev 16(1):3-34
32. Nakae J, Kido Y, Accili D (2001) Distinct and overlapping functions of insulin and IGF-I receptors. Endocr Rev 22(6):818-835 (Pubitemid 34214297)
33. Adams TE et al (2000) Structure and function of the type 1 insulin-like growth factor receptor. Cell Mol Life Sci 57(7):1050-1093 (Pubitemid 30598754)
34. Girnita A et al (2011) Identification of the cathelicidin peptide LL-37 as agonist for the type I insulin-like growth factor receptor. Oncogene 31(3):352-365
35. Petrenko AG et al (2013) Insulin receptor-related receptor as an extracellular pH sensor involved in the regulation of acid-base balance. Biochim Biophys Acta 1834(10):2170-2175
36. Bailyes EM et al (1997) Insulin receptor/IGF-I receptor hybrids are widely distributed in mammalian tissues: quantification of individual receptor species by selective immunoprecipitation and immunoblotting. Biochem J 327(Pt 1):209-215 (Pubitemid 27455481)
37. Belfiore A et al (2009) Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocr Rev 30(6):586-623
38. Evdokimova V et al (2012) IGFBP7 binds to the IGF-1 receptor and blocks its activation by insulin-like growth factors. Sci Signal 5(255):ra92
39. Sepp-Lorenzino L (1998) Structure and function of the insulin-like growth factor I receptor. Breast Cancer Res Treat 47(3):235-253
40. Ullrich A et al (1986) Insulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity. EMBO J 5(10):2503-2512
41. LeRoith D et al (1995) Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocr Rev 16(2):143-163
42. Andersen AS et al (1990) Changing the insulin receptor to possess insulin-like growth factor I ligand specificity. Biochemistry 29(32):7363-7366 (Pubitemid 20251783)
43. Gustafson TA, Rutter WJ (1990) The cysteine-rich domains of the insulin and insulin-like growth factor I receptors are primary determinants of hormone binding specificity. Evidence from receptor chimeras. J Biol Chem 265(30):18663-18667
44. Kjeldsen T et al (1991) The ligand specificities of the insulin receptor and the insulin-like growth factor I receptor reside in different regions of a common binding site. Proc Natl Acad Sci USA 88(10):4404-4408 (Pubitemid 21914548)
45. Schumacher R et al (1991) Insulin and insulin-like growth factor-1 binding specificity is determined by distinct regions of their cognate receptors. J Biol Chem 266(29):19288-19295 (Pubitemid 21908231)
46. Zhang B, Roth RA (1991) Binding properties of chimeric insulin receptors containing the cysteine-rich domain of either the insulin-like growth factor I receptor or the insulin receptor related receptor. Biochemistry 30(21):5113-5117
47. Brown MS, Goldstein JL (1986) A receptor-mediated pathway for cholesterol homeostasis. Science 232(4746):34-47 (Pubitemid 16037973)
48. Backer JM et al (1990) Receptor-mediated internalization of insulin requires a 12-amino acid sequence in the juxtamembrane region of the insulin receptor beta-subunit. J Biol Chem 265(27):16450-16454
49. Hsu D et al (1994) NPXY motif in the insulin-like growth factor-I receptor is required for efficient ligand-mediated receptor internalization and biological signaling. Endocrinology 134(2):744-750 (Pubitemid 24057218)
50. Prager D et al (1994) Human insulin-like growth factor I receptor internalization. Role of the juxtamembrane domain. J Biol Chem 269(16):11934-11937
51. Hanks SK, Quinn AM, Hunter T (1988) The protein kinase family: conserved features and deduced phylogeny of the catalytic domains. Science 241(4861):42-52
52. O'Connor R, Fennelly C, Krause D (2000) Regulation of survival signals from the insulin-like growth factor-I receptor. Biochem Soc Trans 28(2):47-51 (Pubitemid 30103211)
53. Patti ME, Kahn CR (1998) The insulin receptor - a critical link in glucose homeostasis and insulin action. J Basic Clin Physiol Pharmacol 9(2-4):89-109
54. Blakesley VA et al (1996) Signaling via the insulin-like growth factor-I receptor: does it differ from insulin receptor signaling? Cytokine Growth Factor Rev 7(2):153-159 (Pubitemid 27198074)
55. Lammers R et al (1989) Differential signaling potential of insulin- and IGF-1-receptor cytoplasmic domains. EMBO J 8(5):1369-1375 (Pubitemid 19274360)
56. Favelyukis S et al (2001) Structure and autoregulation of the insulin-like growth factor 1 receptor kinase. Nat Struct Biol 8(12):1058-1063 (Pubitemid 33101627)
57. Wang LM et al (1993) IRS-1: essential for insulin- and IL-4-stimulated mitogenesis in hematopoietic cells. Science 261(5128):1591-1594
58. Goel HL et al (2004) Selective modulation of type 1 insulin-like growth factor receptor signaling and functions by beta1 integrins. J Cell Biol 166(3):407-418 (Pubitemid 39031243)
59. Fukushima T et al (2011) Insulin receptor substrates form high-molecular-mass complexes that modulate their availability to insulin/insulin-like growth factor-I receptor tyrosine kinases. Biochem Biophys Res Commun 404(3):767-773
60. Yoshihara H et al (2012) Insulin/insulin-like growth factor (IGF) stimulation abrogates an association between a deubiquitinating enzyme USP7 and insulin receptor substrates (IRSs) followed by proteasomal degradation of IRSs. Biochem Biophys Res Commun 423(1):122-127
61. Wills MK, Jones N (2012) Teaching an old dogma new tricks: twenty years of Shc adaptor signaling. Biochem J 447(1):1-16
62. Werner H, Le Roith D (2000) New concepts in regulation and function of the insulin-like growth factors: implications for understanding normal growth and neoplasia. Cell Mol Life Sci 57(6):932-942 (Pubitemid 30461834)
63. Fukushima T et al (2012) Phosphatidylinositol 3-kinase (PI3K) activity bound to insulin-like growth factor-I (IGF-I) receptor, which is continuously sustained by IGF-I stimulation, is required for IGF-I-induced cell proliferation. J Biol Chem 287(35):29713-29721
64. Alessi DR et al (1996) Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J 15(23):6541-6551 (Pubitemid 26413787)
65. Balendran A et al (1999) Evidence that 3-phosphoinositide-dependent protein kinase-1 mediates phosphorylation of p70 S6 kinase in vivo at Thr-412 as well as Thr-252. J Biol Chem 274(52):37400-37406
66. del Peso L et al (1997) Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science 278(5338):687-689
67. Cardone MH et al (1998) Regulation of cell death protease caspase-9 by phosphorylation. Science 282(5392):1318-1321 (Pubitemid 28524494)
68. Dupont J et al (2003) The insulin-like growth factor axis in cell cycle progression. Horm Metab Res 35(11-12):740-750 (Pubitemid 38058178)
69. Blume-Jensen P, Hunter T (2001) Oncogenic kinase signaling. Nature 411(6835):355-365
70. Zhang D et al (2004) Dual regulation of MMP-2 expression by the type 1 insulin-like growth factor receptor: the phosphatidylinositol 3-kinase/Akt and Raf/ERK pathways transmit opposing signals. J Biol Chem 279(19):19683-19690 (Pubitemid 38623405)
71. Mayo LD, Donner DB (2001) A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc Natl Acad Sci USA 98(20):11598-11603 (Pubitemid 32928774)
72. Peeper DS et al (1997) Ras signaling linked to the cell-cycle machinery by the retinoblastoma protein. Nature 386(6621):177-181 (Pubitemid 27131445)
73. Bates S et al (1998) p14ARF links the tumour suppressors RB and p53. Nature 395(6698):124-125 (Pubitemid 28425642)
74. Sherr CJ, Weber JD (2000) The ARF/p53 pathway. Curr Opin Genet Dev 10(1):94-99 (Pubitemid 30113711)
75. Marchetti A et al (2004) p53 can inhibit cell proliferation through caspase-mediated cleavage of ERK2/MAPK. Cell Death Differ 11(6):596-607 (Pubitemid 38786708)
76. Walsh S, Margolis SS, Kornbluth S (2003) Phosphorylation of the cyclin b1 cytoplasmic retention sequence by mitogen-activated protein kinase and Plx. Mol Cancer Res 1(4):280-289 (Pubitemid 36292613)
77. Strausfeld U et al (1991) Dephosphorylation and activation of a p34cdc2/cyclin B complex in vitro by human CDC25 protein. Nature 351(6323):242-245 (Pubitemid 21896574)
78. Morrione A et al (1996) Grb10: a new substrate of the insulin-like growth factor I receptor. Cancer Res 56(14):3165-3167 (Pubitemid 26242954)
79. Wang J et al (1999) Grb10, a positive, stimulatory signaling adapter in platelet-derived growth factor BB-, insulin-like growth factor I-, and insulin-mediated mitogenesis. Mol Cell Biol 19(9):6217-6228 (Pubitemid 29399326)
80. Uddin S et al (1996) Insulin-like growth factor-1 induces rapid tyrosine phosphorylation of the vav proto-oncogene product. Exp Hematol 24(5):622-627 (Pubitemid 26145053)
81. Zeng L et al (2000) Vav3 mediates receptor protein tyrosine kinase signaling, regulates GTPase activity, modulates cell morphology, and induces cell transformation. Mol Cell Biol 20(24):9212-9224 (Pubitemid 32246108)
82. Beitner-Johnson D, LeRoith D (1995) Insulin-like growth factor-I stimulates tyrosine phosphorylation of endogenous c-Crk. J Biol Chem 270(10):5187-5190
83. Baron V et al (1998) p125Fak focal adhesion kinase is a substrate for the insulin and insulin-like growth factor-I tyrosine kinase receptors. J Biol Chem 273(12):7162-7168 (Pubitemid 28160390)
84. Seely BL et al (1995) Localization of the insulin-like growth factor I receptor binding sites for the SH2 domain proteins p85, Syp, and GTPase activating-protein. J Biol Chem 270(32):19151-19157
85. Arbet-Engels C, Tartare-Deckert S, Eckhart W (1999) C-terminal Src kinase associates with ligand-stimulated insulin-like growth factor-I receptor. J Biol Chem 274(9):5422-5428 (Pubitemid 29109187)
86. Dey BR et al (1998) Interaction of human suppressor of cytokine signaling (SOCS)-2 with the insulin-like growth factor-I receptor. J Biol Chem 273(37):24095-24101 (Pubitemid 28435753)
87. Hermanto U et al (2002) RACK1, an insulin-like growth factor I (IGF-I) receptor-interacting protein, modulates IGF-I-dependent integrin signaling and promotes cell spreading and contact with extracellular matrix. Mol Cell Biol 22(7):2345-2365 (Pubitemid 34224638)
88. Kiely PA, Sant A, O'Connor R (2002) RACK1 is an insulin-like growth factor 1 (IGF-1) receptor-interacting protein that can regulate IGF-1-mediated Akt activation and protection from cell death. J Biol Chem 277(25):22581-22589 (Pubitemid 34967235)
89. O'Connor R et al (1997) Identification of domains of the insulin-like growth factor I receptor that are required for protection from apoptosis. Mol Cell Biol 17(1):427-435 (Pubitemid 26425632)
90. Baserga R (2012) The decline and fall of the IGF-I receptor. J Cell Physiol 228(4):675-679
91. Yee D (2012) Insulin-like growth factor receptor inhibitors: baby or the bathwater? J Natl Cancer Inst 104(13):975-981
92. Werner H (2012) Tumor suppressors govern insulin-like growth factor signaling pathways: implications in metabolism and cancer. Oncogene 31(22):2703-2714
93. Pollak M (2012) The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer 12(3):159-169
94. LeRoith D, Roberts CT Jr (2003) The insulin-like growth factor system and cancer. Cancer Lett 195(2):127-137 (Pubitemid 36588961)
95. Larsson O, Girnita A, Girnita L (2005) Role of insulin-like growth factor 1 receptor signaling in cancer. Br J Cancer 92(12):2097-2101 (Pubitemid 40966242)
96. Pearse BM, Robinson MS (1990) Clathrin, adaptors, and sorting. Annu Rev Cell Biol 6:151-171
97. Robinson MS (1989) Cloning of cDNAs encoding two related 100-kD coated vesicle proteins (alpha-adaptins). J Cell Biol 108(3):833-842
98. Koenig JA, Edwardson JM (1997) Endocytosis and recycling of G-protein-coupled receptors. Trends Pharmacol Sci 18(8):276-287
99. Hicke L (1997) Ubiquitin-dependent internalization and down-regulation of plasma membrane proteins. FASEB J 11(14):1215-1226
100. Hicke L (1999) Gettin' down with ubiquitin: turning off cell-surface receptors, transporters and channels. Trends Cell Biol 9(3):107-112
101. Hicke L (2001) Protein regulation by monoubiquitin. Nat Rev Mol Cell Biol 2(3):195-201
102. Haglund K, Dikic I (2012) The role of ubiquitylation in receptor endocytosis and endosomal sorting. J Cell Sci 125(Pt 2):265-275
103. Andersson ER (2011) The role of endocytosis in activating and regulating signal transduction. Cell Mol Life Sci 69(11):1755-1771
104. Luo Y et al (2011) Endosomal signaling of epidermal growth factor receptors contributes to EGF-stimulated cell cycle progression in primary hepatocytes. Eur J Pharmacol 654(2):173-180
105. Huynh J et al (2012) CSF-1 receptor signaling from endosomes mediates the sustained activation of Erk1/2 and Akt in macrophages. Cell Signal 24(9):1753-1761
106. Shih SC, Sloper-Mould KE, Hicke L (2000) Monoubiquitin carries a novel internalization signal that is appended to activated receptors. EMBO J 19(2):187-198 (Pubitemid 30042701)
107. Acconcia F, Sigismund S, Polo S (2009) Ubiquitin in trafficking: the network at work. Exp Cell Res 315(9):1610-1618
108. Pickart CM (2001) Mechanisms underlying ubiquitination. Annu Rev Biochem 70:503-533
109. Weissman AM (2001) Themes and variations on ubiquitylation. Nat Rev Mol Cell Biol 2(3):169-178
110. Bremm A, Komander D (2011) Emerging roles for Lys11-linked polyubiquitin in cellular regulation. Trends Biochem Sci 36(7):355-363
111. Kulathu Y, Komander D (2012) Atypical ubiquitylation-the unexplored world of polyubiquitin beyond Lys48 and Lys63 linkages. Nat Rev Mol Cell Biol 13(8):508-523
112. Trempe JF (2011) Reading the ubiquitin postal code. Curr Opin Struct Biol 21(6):792-801
113. Nakasone MA et al (2013) Mixed-linkage ubiquitin chains send mixed messages. Structure 21(5):727-740
114. Sepp-Lorenzino L et al (1995) Herbimycin A induces the 20 S proteasome- and ubiquitin-dependent degradation of receptor tyrosine kinases. J Biol Chem 270(28):16580-16587
115. Carelli S et al (2006) Degradation of insulin-like growth factor-I receptor occurs via ubiquitin-proteasome pathway in human lung cancer cells. J Cell Physiol 208(2):354-362 (Pubitemid 43993426)
116. Girnita L, Girnita A, Larsson O (2003) Mdm2-dependent ubiquitination and degradation of the insulin-like growth factor 1 receptor. Proc Natl Acad Sci USA 100(14):8247-8252 (Pubitemid 36842530)
117. Sehat B et al (2008) Identification of c-Cbl as a new ligase for insulin-like growth factor-I receptor with distinct roles from Mdm2 in receptor ubiquitination and endocytosis. Cancer Res 68(14):5669-5677
118. Glogowska A et al (2012) Epidermal growth factor cytoplasmic domain affects ErbB protein degradation by the lysosomal and ubiquitin-proteasome pathway in human cancer cells. Neoplasia 14(5):396-409
119. Ancot F et al (2012) Shedding-generated Met receptor fragments can be routed to either the proteasomal or the lysosomal degradation pathway. Traffic 13(9):1261-1272
120. Vecchione A et al (2003) The Grb10/Nedd4 complex regulates ligand-induced ubiquitination and stability of the insulin-like growth factor I receptor. Mol Cell Biol 23(9):3363-3372 (Pubitemid 36459247)
121. Sehat B et al (2007) Role of ubiquitination in IGF-1 receptor signaling and degradation. PLoS ONE 2(4):e340
122. Dore S, Kar S, Quirion R (1997) Presence and differential internalization of two distinct insulin-like growth factor receptors in rat hippocampal neurons. Neuroscience 78(2):373-383 (Pubitemid 27170329)
123. Segretin ME et al (2003) Insulin-like growth factor-1 receptor regulation in activated human T lymphocytes. Horm Res 59(6):276-280 (Pubitemid 36649383)
124. Zheng H et al (2012) Selective recruitment of G-protein-coupled receptor kinases (GRKs) controls signaling of the insulin-like growth factor 1 receptor. Proc Natl Acad Sci USA 109(18):7055-7060
125. Ceresa BP, Schmid SL (2000) Regulation of signal transduction by endocytosis. Curr Opin Cell Biol 12(2):204-210 (Pubitemid 30142567)
126. Johnson KF, Kornfeld S (1992) The cytoplasmic tail of the mannose 6-phosphate/insulin-like growth factor-II receptor has two signals for lysosomal enzyme sorting in the Golgi. J Cell Biol 119(2):249-257
127. Bremnes B et al (1994) An LI and ML motif in the cytoplasmic tail of the MHC-associated invariant chain mediate rapid internalization. J Cell Sci 107(Pt 7):2021-2032 (Pubitemid 24226451)
128. Miura M, Baserga R (1997) The tyrosine residue at 1250 of the insulin-like growth factor I receptor is required for ligand-mediated internalization. Biochem Biophys Res Commun 239(1):182-185 (Pubitemid 27480338)
129. Morrione A et al (1997) The role of mGrb10alpha in insulin-like growth factor I-mediated growth. J Biol Chem 272(42):26382-26387 (Pubitemid 27458854)
130. Morrione A et al (1999) mGrb10 interacts with Nedd4. J Biol Chem 274(34):24094-24099
131. Monami G, Emiliozzi V, Morrione A (2008) Grb10/Nedd4-mediated multiubiquitination of the insulin-like growth factor receptor regulates receptor internalization. J Cell Physiol 216(2):426-437 (Pubitemid 351898470)
132. Werner H et al (1996) Wild-type and mutant p53 differentially regulate transcription of the insulin-like growth factor I receptor gene. Proc Natl Acad Sci USA 93(16):8318-8323 (Pubitemid 26269555)
133. Girnita L et al (2005) {beta}-Arrestin is crucial for ubiquitination and down-regulation of the insulin-like growth factor-1 receptor by acting as adaptor for the MDM2 E3 ligase. J Biol Chem 280(26):24412-24419 (Pubitemid 40934525)
134. Girnita L et al (2007) Beta-arrestin and Mdm2 mediate IGF-1 receptor-stimulated ERK activation and cell cycle progression. J Biol Chem 282(15):11329-11338 (Pubitemid 47100796)
135. Zwang Y, Yarden Y (2009) Systems biology of growth factor-induced receptor endocytosis. Traffic 10(4):349-363
136. Cao XR et al (2008) Nedd4 controls animal growth by regulating IGF-1 signaling. Sci Signal 1(38):ra5
137. Higashi Y et al (2008) The ubiquitin ligase Nedd4 mediates oxidized low-density lipoprotein-induced downregulation of insulin-like growth factor-1 receptor. Am J Physiol Heart Circ Physiol 295(4):H1684-H1689
138. Romanelli RJ et al (2007) Insulin-like growth factor type-I receptor internalization and recycling mediate the sustained phosphorylation of Akt. J Biol Chem 282(31):22513-22524 (Pubitemid 47267366)
139. Morcavallo A et al (2012) Insulin and insulin-like growth factor II differentially regulate endocytic sorting and stability of insulin receptor isoform A. J Biol Chem 287(14):11422-11436
140. Zheng H et al (2012) beta-Arrestin-biased agonism as the central mechanism of action for insulin-like growth factor 1 receptor-targeting antibodies in Ewing's sarcoma. Proc Natl Acad Sci USA 109(50):20620-20625
141. Mao Y et al (2011) Polyubiquitination of insulin-like growth factor I receptor (IGF-IR) activation loop promotes antibody-induced receptor internalization and down-regulation. J Biol Chem 286(48):41852-41861
142. Broussas M et al (2009) Molecular mechanisms involved in activity of h7C10, a humanized monoclonal antibody, to IGF-1 receptor. Int J Cancer 124(10):2281-2293
143. Vasilcanu R et al (2008) Insulin-like growth factor type-I receptor-dependent phosphorylation of extracellular signal-regulated kinase 1/2 but not Akt (protein kinase B) can be induced by picropodophyllin. Mol Pharmacol 73(3):930-939 (Pubitemid 351397897)
144. Dalle S et al (2001) Insulin and insulin-like growth factor I receptors utilize different G-protein signaling components. J Biol Chem 276(19):15688-15695
145. Rocchi S et al (1996) Interaction of SH2-containing-protein tyrosine phosphatase 2 with the insulin receptor and the insulin-like growth factor-I receptor: studies of the domains involved using the yeast two-hybrid system. Endocrinology 137(11):4944-4952 (Pubitemid 26403338)
146. Maile LA, Clemmons DR (2002) The alphaVbeta3 integrin regulates insulin-like growth factor I (IGF-I) receptor phosphorylation by altering the rate of recruitment of the Src-homology 2-containing phosphotyrosine phosphatase-2 to the activated IGF-I receptor. Endocrinology 143(11):4259-4264 (Pubitemid 35239556)
147. Kuemmerle JF (2006) Occupation of alphavbeta3-integrin by endogenous ligands modulates IGF-I receptor activation and proliferation of human intestinal smooth muscle. Am J Physiol Gastrointest Liver Physiol 290(6):G1194-G1202
148. Buckley DA et al (2002) Regulation of insulin-like growth factor type I (IGF-I) receptor kinase activity by protein tyrosine phosphatase 1B (PTP-1B) and enhanced IGF-I-mediated suppression of apoptosis and motility in PTP-1B-deficient fibroblasts. Mol Cell Biol 22(7):1998-2010 (Pubitemid 34224609)
149. Blanquart C et al (2005) Monitoring the activation state of the insulin-like growth factor-1 receptor and its interaction with protein tyrosine phosphatase 1B using bioluminescence resonance energy transfer. Mol Pharmacol 68(3):885-894 (Pubitemid 41206045)
150. Deng H et al (2010) Over-accumulation of nuclear IGF-1 receptor in tumor cells requires elevated expression of the receptor and the SUMO-conjugating enzyme Ubc9. Biochem Biophys Res Commun 404(2):667-671
151. Sehat B et al (2010) SUMOylation mediates the nuclear translocation and signaling of the IGF-1 receptor. Sci Signal 3(108):ra10
152. Sarfstein R et al (2012) Insulin-like growth factor-I receptor (IGF-IR) translocates to nucleus and autoregulates IGF-IR gene expression in breast cancer cells. J Biol Chem 287(4):2766-2776
153. Asmane I et al (2012) Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: a predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomas. Eur J Cancer 48(16):3027-3035
154. Aleksic T et al (2010) Type 1 insulin-like growth factor receptor translocates to the nucleus of human tumor cells. Cancer Res 70(16):6412-6419
155. Sarfstein R, Werner H (2013) Minireview: nuclear insulin and insulin-like growth factor-1 receptors: a novel paradigm in signal transduction. Endocrinology 154:1672-1679
156. Pandini G et al (2007) Functional responses and in vivo antitumour activity of h7C10: a humanised monoclonal antibody with neutralising activity against the insulin-like growth factor-1 (IGF-1) receptor and insulin/IGF-1 hybrid receptors. Eur J Cancer 43(8):1318-1327 (Pubitemid 46720250)
157. Belfiore A (2007) The role of insulin receptor isoforms and hybrid insulin/IGF-I receptors in human cancer. Curr Pharm Des 13(7):671-686
158. Belfiore A et al (1999) Insulin/IGF-I hybrid receptors play a major role in IGF-I signaling in thyroid cancer. Biochimie 81(4):403-407
159. Riedemann J et al (2007) The EGF receptor interacts with the type 1 IGF receptor and regulates its stability. Biochem Biophys Res Commun 355(3):707-714 (Pubitemid 46330209)
160. Legate KR, Wickstrom SA, Fassler R (2009) Genetic and cell biological analysis of integrin outside-in signaling. Genes Dev 23(4):397-418
161. Ivaska J, Heino J (2010) Interplay between cell adhesion and growth factor receptors: from the plasma membrane to the endosomes. Cell Tissue Res 339(1):111-120
162. Maile LA et al (2002) Insulin-like growth factor I increases alpha Vbeta 3 affinity by increasing the amount of integrin-associated protein that is associated with non-raft domains of the cellular membrane. J Biol Chem 277(3):1800-1805 (Pubitemid 34968752)
163. Manes S et al (1999) Concerted activity of tyrosine phosphatase SHP-2 and focal adhesion kinase in regulation of cell motility. Mol Cell Biol 19(4):3125-3135 (Pubitemid 29144557)
164. Ling Y et al (2005) DOK1 mediates SHP-2 binding to the alphaVbeta3 integrin and thereby regulates insulin-like growth factor I signaling in cultured vascular smooth muscle cells. J Biol Chem 280(5):3151-3158 (Pubitemid 40223776)
165. Jones JI et al (1996) Ligand occupancy of the alpha-V-beta3 integrin is necessary for smooth muscle cells to migrate in response to insulin-like growth factor. Proc Natl Acad Sci USA 93(6):2482-2487 (Pubitemid 26104797)
166. Brooks PC et al (1997) Insulin-like growth factor receptor cooperates with integrin alpha v beta 5 to promote tumor cell dissemination in vivo. J Clin Invest 99(6):1390-1398 (Pubitemid 27142777)
167. Ling Y, Maile LA, Clemmons DR (2003) Tyrosine phosphorylation of the beta3-subunit of the alphaVbeta3 integrin is required for embrane association of the tyrosine phosphatase SHP-2 and its further recruitment to the insulin-like growth factor I receptor. Mol Endocrinol 17(9):1824-1833 (Pubitemid 37072298)
168. Maile LA, Badley-Clarke J, Clemmons DR (2003) The association between integrin-associated protein and SHPS-1 regulates insulin-like growth factor-I receptor signaling in vascular smooth muscle cells. Mol Biol Cell 14(9):3519-3528 (Pubitemid 37151605)
169. Clemmons DR, Maile LA (2005) Interaction between insulin-like growth factor-I receptor and alphaVbeta3 integrin linked signaling pathways: cellular responses to changes in multiple signaling inputs. Mol Endocrinol 19(1):1-11 (Pubitemid 40065954)
170. Clemmons DR, Maile LA (2003) Minireview: integral membrane proteins that function coordinately with the insulin-like growth factor I receptor to regulate intracellular signaling. Endocrinology 144(5):1664-1670 (Pubitemid 36543301)
171. Edderkaoui M et al (2007) Insulin-like growth factor-I receptor mediates the prosurvival effect of fibronectin. J Biol Chem 282(37):26646-26655 (Pubitemid 47501963)
172. Shakibaei M et al (1999) Signal transduction by beta1 integrin receptors in human chondrocytes in vitro: collaboration with the insulin-like growth factor-I receptor. Biochem J 342(Pt 3):615-623 (Pubitemid 29452646)
173. Kiely PA et al (2006) Insulin-like growth factor I controls a mutually exclusive association of RACK1 with protein phosphatase 2A and beta1 integrin to promote cell migration. Mol Cell Biol 26(11):4041-4051 (Pubitemid 43788008)
174. O'Donovan HC, Kiely PA, O'Connor R (2007) Effects of RACK1 on cell migration and IGF-I signaling in cardiomyocytes are not dependent on an association with the IGF-IR. Cell Signal 19(12):2588-2595 (Pubitemid 47531937)
175. Saegusa J et al (2009) The direct binding of insulin-like growth factor-1 (IGF-1) to integrin alphavbeta3 is involved in IGF-1 signaling. J Biol Chem 284(36):24106-24114
176. Fujita M et al (2013) An integrin-binding-defective mutant of insulin-like growth factor-1 (R36E/R37E IGF1) acts as a dominant-negative antagonist of IGF1R and suppresses tumorigenesis, while the mutant still binds to IGF1R. J Biol Chem
177. Fujita M et al (2012) Cross-talk between integrin alpha6beta4 and insulin-like growth factor-1 receptor (IGF1R) through direct alpha6beta4 binding to IGF1 and subsequent alpha-6beta4-IGF1-IGF1R ternary complex formation in anchorage-independent conditions. J Biol Chem 287(15):12491-12500
178. Fujita M et al (2013) An integrin binding-defective mutant of insulin-like growth factor-1 (R36E/R37E IGF1) acts as a dominant-negative antagonist of the IGF1 receptor (IGF1R) and suppresses tumorigenesis but still binds to IGF1R. J Biol Chem 288(27):19593-19603
179. Waters C, Pyne S, Pyne NJ (2004) The role of G-protein coupled receptors and associated proteins in receptor tyrosine kinase signal transduction. Semin Cell Dev Biol 15(3):309-323 (Pubitemid 38581999)
180. Daub H et al (1997) Signal characteristics of G-protein-transactivated EGF receptor. EMBO J 16(23):7032-7044 (Pubitemid 27520803)
181. Pyne NJ, Pyne S (2011) Receptor tyrosine kinase-G-protein-coupled receptor signaling platforms: out of the shadow? Trends Pharmacol Sci 32(8):443-450
182. Rao GN, Delafontaine P, Runge MS (1995) Thrombin stimulates phosphorylation of insulin-like growth factor-1 receptor, insulin receptor substrate-1, and phospholipase C-gamma 1 in rat aortic smooth muscle cells. J Biol Chem 270(46):27871-27875
183. Zhao D et al (2011) Insulin-like growth factor-1 receptor transactivation modulates the inflammatory and proliferative responses of neurotensin in human colonic epithelial cells. J Biol Chem 286(8):6092-6099
184. Oligny-Longpre G et al (2012) Engagement of beta-arrestin by transactivated insulin-like growth factor receptor is needed for V2 vasopressin receptor-stimulated ERK1/2 activation. Proc Natl Acad Sci USA 109(17):E1028-E1037
185. Luttrell LM et al (1995) G beta gamma subunits mediate mitogen-activated protein kinase activation by the tyrosine kinase insulin-like growth factor 1 receptor. J Biol Chem 270(28):16495-16498
186. Luttrell L et al (1990) A pertussis toxin-sensitive G-protein mediates some aspects of insulin action in BC3H-1 murine myocytes. J Biol Chem 265(28):16873-16879
187. Delcourt N, Bockaert J, Marin P (2007) GPCR-jacking: from a new route in RTK signaling to a new concept in GPCR activation. Trends Pharmacol Sci 28(12):602-607 (Pubitemid 350166573)
188. Heyworth CM et al (1986) The action of islet activating-protein (pertussis toxin) on insulin's ability to inhibit adenylate cyclase and activate cyclic AMP phosphodiesterases in hepatocytes. Biochem J 235(1):145-149 (Pubitemid 16041985)
189. Rothenberg PL, Kahn CR (1988) Insulin inhibits pertussis toxin-catalyzed ADP-ribosylation of G-proteins. Evidence for a novel interaction between insulin receptors and G-proteins. J Biol Chem 263(30):15546-15552
190. Hallak H et al (2000) Association of heterotrimeric G(i) with the insulin-like growth factor-I receptor. Release of G(betagamma) subunits upon receptor activation. J Biol Chem 275(4):2255-2258 (Pubitemid 30081978)
191. Lin FT, Daaka Y, Lefkowitz RJ (1998) beta-Arrestins regulate mitogenic signaling and clathrin-mediated endocytosis of the insulin-like growth factor I receptor. J Biol Chem 273(48):31640-31643 (Pubitemid 29177090)
192. Shenoy SK et al (2006) beta-Arrestin-dependent, G-protein-independent ERK1/2 activation by the beta2 adrenergic receptor. J Biol Chem 281(2):1261-1273
193. Lefkowitz RJ, Shenoy SK (2005) Transduction of receptor signals by beta-arrestins. Science 308(5721):512-517
194. Lefkowitz RJ (2004) Historical review: a brief history and personal retrospective of seven-transmembrane receptors. Trends Pharmacol Sci 25(8):413-422
195. Shenoy SK, Lefkowitz RJ (2003) Multifaceted roles of beta-arrestins in the regulation of seven-membrane-spanning receptor trafficking and signaling. Biochem J 375(Pt 3):503-515 (Pubitemid 37433499)
196. DeWire SM et al (2007) Beta-arrestins and cell signaling. Annu Rev Physiol 69:483-510
197. Reiter E, Lefkowitz RJ (2006) GRKs and beta-arrestins: roles in receptor silencing, trafficking and signaling. Trends Endocrinol Metab 17(4):159-165
198. Gao J, Li J, Ma L (2005) Regulation of EGF-induced ERK/MAPK activation and EGFR internalization by G-protein-coupled receptor kinase 2. Acta Biochim Biophys Sin (Shanghai) 37(8):525-531 (Pubitemid 41608065)
199. Freedman NJ et al (2002) Phosphorylation of the platelet-derived growth factor receptor-beta and epidermal growth factor receptor by G-protein-coupled receptor kinase-2. Mechanisms for selectivity of desensitization. J Biol Chem 277(50):48261-48269 (Pubitemid 35470778)
200. Usui I et al (2004) GRK2 is an endogenous protein inhibitor of the insulin signaling pathway for glucose transport stimulation. EMBO J 23(14):2821-2829 (Pubitemid 39013554)
201. Pitcher JA, Freedman NJ, Lefkowitz RJ (1998) G-protein-coupled receptor kinases. Annu Rev Biochem 67:653-692
202. Perrault R et al (2011) Tyrosine kinase-independent activation of extracellular-regulated kinase (ERK) 1/2 by the insulin-like growth factor-1 receptor. Cell Signal 23(4):739-746
203. Frattali AL, Treadway JL, Pessin JE (1992) Insulin/IGF-1 hybrid receptors: implications for the dominant-negative phenotype in syndromes of insulin resistance. J Cell Biochem 48(1):43-50
204. Povsic TJ, Kohout TA, Lefkowitz RJ (2003) Beta-arrestin1 mediates insulin-like growth factor 1 (IGF-1) activation of phosphatidylinositol 3-kinase (PI3K) and anti-apoptosis. J Biol Chem 278(51):51334-51339 (Pubitemid 38020372)
205. Arteaga CL (1992) Interference of the IGF system as a strategy to inhibit breast cancer growth. Breast Cancer Res Treat 22(1):101-106
206. Kalebic T, Tsokos M, Helman LJ (1994) In vivo treatment with antibody against IGF-1 receptor suppresses growth of human rhabdomyosarcoma and down-regulates p34cdc2. Cancer Res 54(21):5531-5534
207. Trojan J et al (1992) Loss of tumorigenicity of rat glioblastoma directed by episome-based antisense cDNA transcription of insulin-like growth factor I. Proc Natl Acad Sci USA 89(11):4874-4878
208. Resnicoff M et al (1994) Rat glioblastoma cells expressing an antisense RNA to the insulin-like growth factor-1 (IGF-1) receptor are nontumorigenic and induce regression of wild-type tumors. Cancer Res 54(8):2218-2222 (Pubitemid 24138698)
209. Resnicoff M et al (1994) Growth inhibition of human melanoma cells in nude mice by antisense strategies to the type 1 insulin-like growth factor receptor. Cancer Res 54(18):4848-4850 (Pubitemid 24289413)
210. Shapiro DN et al (1994) Antisense-mediated reduction in insulin-like growth factor-I receptor expression suppresses the malignant phenotype of a human alveolar rhabdomyosarcoma. J Clin Invest 94(3):1235-1242 (Pubitemid 24286468)
211. Reiss K et al (1998) Inhibition of tumor growth by a dominant negative mutant of the insulin-like growth factor I receptor with a bystander effect. Clin Cancer Res 4(11):2647-2655 (Pubitemid 28523490)
212. Long L et al (1995) Loss of the metastatic phenotype in murine carcinoma cells expressing an antisense RNA to the insulin-like growth factor receptor. Cancer Res 55(5):1006-1009
213. Dunn SE et al (1998) A dominant negative mutant of the insulin-like growth factor-I receptor inhibits the adhesion, invasion, and metastasis of breast cancer. Cancer Res 58(15):3353-3361 (Pubitemid 28371076)
214. Kanter-Lewensohn L et al (2000) Tamoxifen-induced cell death in malignant melanoma cells: possible involvement of the insulin-like growth factor-1 (IGF-1) pathway. Mol Cell Endocrinol 165(1-2):131-137 (Pubitemid 30625191)
215. Scartozzi M et al (2011) State of the art and future perspectives for the use of insulin-like growth factor receptor 1 (IGF-1R) targeted treatment strategies in solid tumors. Discov Med 11(57):144-153
216. Baserga R (2000) The contradictions of the insulin-like growth factor 1 receptor. Oncogene 19(49):5574-5581
217. Kanter-Lewensohn L et al (2000) Expression of insulin-like growth factor-1 receptor (IGF-1R) and p27Kip1 in melanocytic tumors: a potential regulatory role of IGF-1 pathway in distribution of p27Kip1 between different cyclins. Growth Factors 17(3):193-202 (Pubitemid 30103478)
218. Navab R et al (2001) Inhibition of endosomal insulin-like growth factor-I processing by cysteine proteinase inhibitors blocks receptor-mediated functions. J Biol Chem 276(17):13644-13649
219. Ren SG et al (1992) Somatostatin analog induces insulin-like growth factor binding-protein-1 (IGFBP-1) expression in human hepatoma cells. Endocrinology 131(5):2479-2481
220. Pietrzkowski Z et al (1993) Inhibition of growth of prostatic cancer cell lines by peptide analogues of insulin-like growth factor 1. Cancer Res 53(5):1102-1106 (Pubitemid 23087914)
221. Rohlik QT et al (1987) An antibody to the receptor for insulin-like growth factor I inhibits the growth of MCF-7 cells in tissue culture. Biochem Biophys Res Commun 149(1):276-281 (Pubitemid 17162972)
222. Rosenzweig SA, Atreya HS (2010) Defining the pathway to insulin-like growth factor system targeting in cancer. Biochem Pharmacol 80(8):1115-1124
223. Firth SM, Baxter RC (2002) Cellular actions of the insulin-like growth factor binding-proteins. Endocr Rev 23(6):824-854 (Pubitemid 35454590)
224. Dransfield DT et al (2010) A human monoclonal antibody against insulin-like growth factor-II blocks the growth of human hepatocellular carcinoma cell lines in vitro and in vivo. Mol Cancer Ther 9(6):1809-1819
225. Gao J et al (2011) Dual IGF-I/II-neutralizing antibody MEDI-573 potently inhibits IGF signaling and tumor growth. Cancer Res 71(3):1029-1040
226. Zhao Q et al (2011) Human monoclonal antibody fragments binding to insulin-like growth factors I and II with picomolar affinity. Mol Cancer Ther 10(9):1677-1685
227. Feng Y et al (2006) Novel human monoclonal antibodies to insulin-like growth factor (IGF)-II that potently inhibit the IGF receptor type I signal transduction function. Mol Cancer Ther 5(1):114-120
228. Olmos D et al (2011) Targeting the insulin-like growth factor 1 receptor in Ewing's sarcoma: reality and expectations. Sarcoma 2011(402508):402508
229. Olmos D et al (2009) Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study. Lancet Oncol 11(2):129-135
230. Juergens H et al (2011) Preliminary efficacy of the anti-insulin-like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma. J Clin Oncol 29(34):4534-4540
231. Gualberto A et al (2010) Molecular analysis of non-small cell lung cancer identifies subsets with different sensitivity to insulin-like growth factor I receptor inhibition. Clin Cancer Res 16(18):4654-4665
232. Corral J et al (2011) Pathologic complete responses after chemotherapy plus figitumumab in stage IV non-small-cell lung cancer. J Clin Oncol 29(7):e163-e165
233. Burgaud JL, Resnicoff M, Baserga R (1995) Mutant IGF-I receptors as dominant negatives for growth and transformation. Biochem Biophys Res Commun 214(2):475-481
234. Li S et al (1994) Mitogenicity and transforming activity of the insulin-like growth factor-I receptor with mutations in the tyrosine kinase domain. J Biol Chem 269(51):32558-32564
235. Kalebic T et al (1998) Expression of a kinase-deficient IGF-I-R suppresses tumorigenicity of rhabdomyosarcoma cells constitutively expressing a wild type IGF-I-R. Int J Cancer 76(2):223-227 (Pubitemid 28180376)
236. Scotlandi K et al (2002) Expression of an IGF-I receptor dominant negative mutant induces apoptosis, inhibits tumorigenesis and enhances chemosensitivity in Ewing's sarcoma cells. Int J Cancer 101(1):11-16 (Pubitemid 34832991)
237. Brodt P, Samani A, Navab R (2000) Inhibition of the type I insulin-like growth factor receptor expression and signaling: novel strategies for antimetastatic therapy. Biochem Pharmacol 60(8):1101-1107
238. Buck E, Mulvihill M (2011) Small molecule inhibitors of the IGF-1R/IR axis for the treatment of cancer. Expert Opin Investig Drugs 20(5):605-621
239. Jin M et al (2012) Small-molecule ATP-competitive dual IGF-1R and insulin receptor inhibitors: structural insights, chemical diversity and molecular evolution. Future Med Chem 4(3):315-328
240. Buck E et al (2010) Compensatory insulin receptor (IR) activation on inhibition of insulin-like growth factor-1 receptor (IGF-1R): rationale for cotargeting IGF-1R and IR in cancer. Mol Cancer Ther 9(10):2652-2664
241. Ulanet DB et al (2010) Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy. Proc Natl Acad Sci USA 107(24):10791-10798
242. Mitsiades CS et al (2004) Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell 5(3):221-230 (Pubitemid 38402114)
243. Scotlandi K et al (2005) Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors. Cancer Res 65(9):3868-3876 (Pubitemid 40616368)
244. Mulvihill MJ et al (2009) Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor. Future Med Chem 1(6):1153-1171
245. Vasilcanu D et al (2004) The cyclolignan PPP induces activation loop-specific inhibition of tyrosine phosphorylation of the insulin-like growth factor-1 receptor. Link to the phosphatidyl inositol-3 kinase/Akt apoptotic pathway. Oncogene 23(47):7854-7862 (Pubitemid 39457035)
246. Ahlen J et al (2005) Insulin-like growth factor type 1 receptor expression correlates to good prognosis in highly malignant soft tissue sarcoma. Clin Cancer Res 11(1):206-216 (Pubitemid 40075797)
247. Economou MA et al (2005) Receptors for the liver synthesized growth factors IGF-1 and HGF/SF in uveal melanoma: intercorrelation and prognostic implications. Invest Ophthalmol Vis Sci 46(12):4372-4375 (Pubitemid 44264528)
248. Economou MA et al (2008) Oral picropodophyllin (PPP) is well tolerated in vivo and inhibits IGF-1R expression and growth of uveal melanoma. Invest Ophthalmol Vis Sci 49(6):2337-2342
249. Menu E et al (2006) Inhibiting the IGF-1 receptor tyrosine kinase with the cyclolignan PPP: an in vitro and in vivo study in the 5T33MM mouse model. Blood 107(2):655-660 (Pubitemid 43076391)
250. Natalishvili N et al (2009) Aberrant intracellular IGF-1R beta-subunit makes receptor knockout cells (IGF1R-/-) susceptible to oncogenic transformation. Exp Cell Res 315(8):1458-1467
251. Razuvaev A et al (2007) The cyclolignan picropodophyllin attenuates intimal hyperplasia after rat carotid balloon injury by blocking insulin-like growth factor-1 receptor signaling. J Vasc Surg 46(1):108-115 (Pubitemid 46990746)
252. Stromberg T et al (2006) IGF-1 receptor tyrosine kinase inhibition by the cyclolignan PPP induces G2/M-phase accumulation and apoptosis in multiple myeloma cells. Blood 107(2):669-678 (Pubitemid 43076393)
253. Vitale M et al (2008) New picropodophyllin analogs via palladium-catalyzed allylic alkylation-Hiyama cross-coupling sequences. J Org Chem 73(15):5795-5805
254. Conti L et al (2007) In the absence of IGF-1 signaling, IFN-gamma suppresses human malignant T-cell growth. Blood 109(6):2496-2504 (Pubitemid 46425894)
255. Jernberg-Wiklund H, Nilsson K (2007) Control of apoptosis in human multiple myeloma by insulin-like growth factor I (IGF-I). Adv Cancer Res 97:139-165 (Pubitemid 46541692)
256. Menu E et al (2007) Targeting the IGF-1R using picropodophyllin in the therapeutical 5T2MM mouse model of multiple myeloma: beneficial effects on tumor growth, angiogenesis, bone disease and survival. Int J Cancer 121(8):1857-1861 (Pubitemid 47417307)
257. Nussbaum T et al (2008) Autocrine insulin-like growth factor-II stimulation of tumor cell migration is a progression step in human hepatocarcinogenesis. Hepatology 48(1):146-156 (Pubitemid 351975539)
258. Klinakis A et al (2009) Igf1r as a therapeutic target in a mouse model of basal-like breast cancer. Proc Natl Acad Sci USA 106(7):2359-2364
259. Hashemi J et al (2011) Molecular characterization of acquired tolerance of tumor cells to picropodophyllin (PPP). PLoS ONE 6(3):e14757
260. Rosengren L et al (2006) IGF-1R tyrosine kinase expression and dependency in clones of IGF-1R knockout cells (R-). Biochem Biophys Res Commun 347(4):1059-1066 (Pubitemid 44137345)
261. Ekman S et al (2011) Clinical phase I study with an insulin-like growth factor-1 receptor inhibitor: experiences in patients with squamous non-small cell lung carcinoma. Acta Oncol 50(3):441-447
262. Dong JY et al (2011) A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activity. MAbs 3(3):273-288
263. Rowinsky EK et al (2007) IMC-A12, a human IgG, monoclonal antibody to the insulin-like growth factor I receptor. Clin Cancer Res 13(18):5549S-5555S (Pubitemid 47510386)
264. Runnels HA et al (2010) Human monoclonal antibodies to the insulin-like growth factor 1 receptor inhibit receptor activation and tumor growth in preclinical studies. Adv Ther 27(7):458-475
265. Wang Y et al (2005) Inhibition of insulin-like growth factor-I receptor (IGF-IR) signaling and tumor cell growth by a fully human neutralizing anti-IGF-IR antibody. Mol Cancer Ther 4(8):1214-1221 (Pubitemid 41149569)
266. Garofalo C et al (2012) Identification of common and distinctive mechanisms of resistance to different anti-IGF-IR agents in Ewing's sarcoma. Mol Endocrinol 26(9):1603-1616
267. Takahashi K, Yonezawa K, Nishimoto I (1995) Insulin-like growth factor I receptor activated by a transmembrane mutation. J Biol Chem 270(32):19041-19045
268. Craparo A, O'Neill TJ, Gustafson TA (1995) Non-SH2 domains within insulin receptor substrate-1 and SHC mediate their phosphotyrosine-dependent interaction with the NPEY motif of the insulin-like growth factor I receptor. J Biol Chem 270(26):15639-15643
269. Tartare-Deckert S et al (1995) Evidence for a differential interaction of SHC and the insulin receptor substrate-1 (IRS-1) with the insulin-like growth factor-I (IGF-I) receptor in the yeast two-hybrid system. J Biol Chem 270(40):23456-23460
270. He W et al (1996) Interaction of insulin receptor substrate-2 (IRS-2) with the insulin and insulin-like growth factor I receptors. Evidence for two distinct phosphotyrosine-dependent interaction domains within IRS-2. J Biol Chem 271(20):11641-11645
271. Xu P, Jacobs AR, Taylor SI (1999) Interaction of insulin receptor substrate 3 with insulin receptor, insulin receptor-related receptor, insulin-like growth factor-1 receptor, and downstream signaling-proteins. J Biol Chem 274(21):15262-15270
272. Dey BR et al (1996) Evidence for the direct interaction of the insulin-like growth factor I receptor with IRS-1, Shc, and Grb10. Mol Endocrinol 10(6):631-641 (Pubitemid 26176271)
273. Beitner-Johnson D et al (1995) Regulation of insulin-like growth factor I receptor gene expression by Sp1: physical and functional interactions of Sp1 at GC boxes and at a CT element. Mol Endocrinol 9(9):1147-1156
274. Koval AP et al (1998) Interaction in vitro of the product of the c-Crk-II proto-oncogene with the insulin-like growth factor I receptor. Biochem J 330(Pt 2):923-932 (Pubitemid 28111998)
275. Miura M, Li S, Baserga R (1995) Effect of a mutation at tyrosine 950 of the insulin-like growth factor I receptor on the growth and transformation of cells. Cancer Res 55(3):663-667
276. Jiang Y et al (1996) Effect of tyrosine mutations on the kinase activity and transforming potential of an oncogenic human insulin-like growth factor I receptor. J Biol Chem 271(1):160-167
277. Esposito DL et al (1997) Tyrosine residues in the C-terminal domain of the insulin-like growth factor-I receptor mediate mitogenic and tumorigenic signals. Endocrinology 138(7):2979-2988
278. Yamasaki H et al (1992) Human insulin-like growth factor I receptor 950tyrosine is required for somatotroph growth factor signal transduction. J Biol Chem 267(29):20953-20958
279. Kato H et al (1993) Role of tyrosine kinase activity in signal transduction by the insulin-like growth factor-I (IGF-I) receptor. Characterization of kinase-deficient IGF-I receptors and the action of an IGF-I-mimetic antibody (alpha IR-3). J Biol Chem 268(4):2655-2661 (Pubitemid 23057892)
280. Kelly GM et al (2012) Serine phosphorylation of the insulin-like growth factor I (IGF-1) receptor C-terminal tail restrains kinase activity and cell growth. J Biol Chem 287(33):28180-28194
281. Kruis T et al (2010) Heterozygous mutation within a kinase-conserved motif of the insulin-like growth factor I receptor causes intrauterine and postnatal growth retardation. J Clin Endocrinol Metab 95(3):1137-1142
282. Stannard B et al (1995) Single tyrosine substitution in the insulin-like growth factor I receptor inhibits ligand-induced receptor autophosphorylation and internalization, but not mitogenesis. Endocrinology 136(11):4918-4924
283. Hernandez-Sanchez C et al (1995) The role of the tyrosine kinase domain of the insulin-like growth factor-I receptor in intracellular signaling, cellular proliferation, and tumorigenesis. J Biol Chem 270(49):29176-29181
284. Blakesley VA et al (1995) Mutation of a conserved amino acid residue (tryptophan 1173) in the tyrosine kinase domain of the IGF-I receptor abolishes autophosphorylation but does not eliminate biologic function. J Biol Chem 270(6):2764-2769
285. Brodt P et al (2001) Cooperative regulation of the invasive and metastatic phenotypes by different domains of the type I insulin-like growth factor receptor beta subunit. J Biol Chem 276(36):33608-33615
286. Miura M et al (1995) Different effects on mitogenesis and transformation of a mutation at tyrosine 1251 of the insulin-like growth factor I receptor. J Biol Chem 270(38):22639-22644
287. Craparo A, Freund R, Gustafson TA (1997) 14-3-3 (epsilon) interacts with the insulin-like growth factor I receptor and insulin receptor substrate I in a phosphoserine-dependent manner. J Biol Chem 272(17):11663-11669 (Pubitemid 27184180)
288. Furlanetto RW et al (1997) 14-3-3 proteins interact with the insulin-like growth factor receptor but not the insulin receptor. Biochem J 327(Pt 3):765-771
289. Peruzzi F et al (2001) Anti-apoptotic signaling of the insulin-like growth factor-I receptor through mitochondrial translocation of c-Raf and Nedd4. J Biol Chem 276(28):25990-25996
290. Li S, Resnicoff M, Baserga R (1996) Effect of mutations at serines 1280-1283 on the mitogenic and transforming activities of the insulin-like growth factor I receptor. J Biol Chem 271(21):12254-12260 (Pubitemid 26160887)
291. Dews M et al (2000) Domains of the insulin-like growth factor I receptor required for the activation of extracellular signal-regulated kinases. Endocrinology 141(4):1289-1300 (Pubitemid 32269095)
292. Hongo A et al (1996) Mutational analysis of the mitogenic and transforming activities of the insulin-like growth factor I receptor. Oncogene 12(6):1231-1238 (Pubitemid 26127254)
293. Lamothe B et al (1995) Interaction of p85 subunit of PI 3-kinase with insulin and IGF-1 receptors analysed by using the two-hybrid system. FEBS Lett 373(1):51-55
294. O'Connor R (2003) Regulation of IGF-I receptor signaling in tumor cells. Horm Metab Res 35(11-12):771-777
295. Fernandez CA et al (2010) The anti-angiogenic peptide, loop 6, binds insulin-like growth factor-1 receptor. J Biol Chem 285(53):41886-41895
296. Dey BR, Furlanetto RW, Nissley P (2000) Suppressor of cytokine signaling (SOCS)-3 protein interacts with the insulin-like growth factor-I receptor. Biochem Biophys Res Commun 278(1):38-43
297. Dey BR, Furlanetto RW, Nissley SP (1998) Cloning of human p55 gamma, a regulatory subunit of phosphatidylinositol 3-kinase, by a yeast two-hybrid library screen with the insulin-like growth factor-I receptor. Gene 209(1-2):175-183 (Pubitemid 28149632)
298. Gual P et al (1998) Interaction of Janus kinases JAK-1 and JAK-2 with the insulin receptor and the insulin-like growth factor-1 receptor. Endocrinology 139(3):884-893 (Pubitemid 28510102)